Search

Meeting Coverage:

Association for Research in Vision & Ophthalmology

ARVO: 2025

0 seconds of 0 secondsVolume 0%

00:00

00:00

00:00

Treating DR with Axitinib

Neal S. Shah, MD

Show Description +

Dr. Shah explains the longitudinal quantitative ultra-widefield retinal leakage assessment after a single axitinib hydrogel injection (OTX-TKI, Ocular Therapeutix) from the HELIOS trial for diabetic retinopathy.

Posted: 5/16/2025

Keywords:

axitinib

•

Diabetic Retinopathy

•

Ocular Therapeutix

•

longitudinal

•

leakage

•

axitinib hydrogel injection

•

OTX-TKI

•

TKI

•

tyrosine-kinase inhibitor

•

Clinical Trials

•

retina-meeting-recap

Up Next

Phase 2 Data on Gene Therapy for AMD

Phase 2 Data on Gene Therapy for AMD

Christine Kay, MD

OCS-01 (Oculis) in DME: A Phase 3 Update

OCS-01 (Oculis) in DME: A Phase 3 Update

Carl Danzig, MD

Gene Therapy for Wet AMD: New Phase 2 Data

Gene Therapy for Wet AMD: New Phase 2 Data

Dante Pieramici MD

Surgical Pearls for Sickle Cell Retinopathy

Surgical Pearls for Sickle Cell Retinopathy

Jennifer I. Lim, MD

Dosing Considerations with 8 mg Aflibercept

Dosing Considerations with 8 mg Aflibercept

Mark R. Barakat, MD

Pegcetacoplan in the Real World: Year 1

Pegcetacoplan in the Real World: Year 1

Mengxi Shen, MD, PhD

Phase 2a Data Revealed for AVD-104 (Aviceda)

Phase 2a Data Revealed for AVD-104 (Aviceda)

Baruch D. Kuppermann, MD, PhD

Real-World Data for 8 mg Aflibercept

Real-World Data for 8 mg Aflibercept

Vasileios Konidaris, MD, PhD

$The Benefits of Refractive Vitrectomy for SVOs$

The Benefits of Refractive Vitrectomy for SVOs

Paulo Eduardo Stanga, MD

Bariatric Surgery Versus GLP-1 Receptor Agonists

Bariatric Surgery Versus GLP-1 Receptor Agonists

Christabel Chan, MD

Back to All Videos

Treating DR with Axitinib

Neal S. Shah, MD

Dr. Shah explains the longitudinal quantitative ultra-widefield retinal leakage assessment after a single axitinib hydrogel injection (OTX-TKI, Ocular Therapeutix) from the HELIOS trial for diabetic retinopathy.

Posted: 5/16/2025

Keywords:

axitinib

•

Diabetic Retinopathy

•

Ocular Therapeutix

•

longitudinal

•

leakage

•

axitinib hydrogel injection

•

OTX-TKI

•

TKI

•

tyrosine-kinase inhibitor

•

Clinical Trials

•

retina-meeting-recap

Please log in to leave a comment.

More From ARVO: 2025 Coverage

Phase 2a Data Revealed for AVD-104 (Aviceda)

Phase 2a Data Revealed for AVD-104 (Aviceda)

Baruch D. Kuppermann, MD, PhD

Real-World Data for 8 mg Aflibercept

Real-World Data for 8 mg Aflibercept

Vasileios Konidaris, MD, PhD

$The Benefits of Refractive Vitrectomy for SVOs$

The Benefits of Refractive Vitrectomy for SVOs

Paulo Eduardo Stanga, MD

Bariatric Surgery Versus GLP-1 Receptor Agonists

Bariatric Surgery Versus GLP-1 Receptor Agonists

Christabel Chan, MD

Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of ARVO: 2025.